PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/649,378
Filing Date	August 25, 2003
First Named Inventor	Alan M. Fogelman
Group Art Unit	1614
Examiner Name	Jeffrey E. Russel
Total Number of Pages in This Submission	
Attorney Docket Number	407T-911310US

ENCLOSURES ***(check all that apply)***

- [ ] Fee Transmittal Form
  - [ ] Fee Attached
- [ ] Amendment / Response
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [X] Information Disclosure Statement
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts/ Incomplete Application
  - [ ] Response to Missing Parts under 37 CFR 1.52 or 1.53
- [ ] Assignment Papers *(for an Application)*
- [ ] Drawing(s)
- [ ] Licensing-related Papers
- [ ] Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Small Entity Statement
- [ ] Request for Refund
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group (*Appeal Notice, Brief, Reply Brief*)
- [ ] Proprietary Information
- [ ] Status Letter
- [X] Additional Enclosure(s) *(please identify below)*:

receipt acknowledgment postcard
26 Enclosed References
2 PTO-form 1449's

Authorization to Charge Deposit Account
Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm *or* Individual name	Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group P.C.
Signature	
Date	May 18, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231 on this date: May 18, 2005

Typed or printed name	Chianti Appling		
Signature		Date	5/18/05

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 18, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By _____
Chianti Appling

Attorney Docket No. 407T-911310US
Client Ref. No. 2000-462-6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	
Alan M. Fogelman, et al.	Examiner: Jeffrey E. Russel
Application No.: 10/649,378	Art Unit: 1654
Filed: August 25, 2003	
For: ORALLY ADMINISTERED SMALL PEPTIDES SYNERGIZE STATIN ACTIVITY	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 and § 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/896,841 filed June 29, 2001. *An additional 1449 form citing an additional reference is also enclosed. A copy of the newly cited reference is enclosed.* Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/896,841 filed June 29, 2001 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner. It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

05/24/2005 WASFAW1 00000002 500893 10649378
01 FC:1806 180.00 DA

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the first Office Action and more than three months after the filing date, but prior to the Notice of Allowance or Final Office Action.

Please deduct $180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Tom Hunter , J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Copy From Parent

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	**10/649,378**
Filing Date	**August 26, 2003**
First Named Inventor	**Alan M. Fogelman**
Group Art Unit	**1654**
Examiner Name	**Jeffrey E. Russel**
Attorney Docket Number	**407T-911310US**
Date Submitted	**May 18, 2005**

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	1.	5,733,879		Rosseneu et al.	3/31/1998	
	2.	6,004,925		Dasseux et al.	12/21/1999	
	3.	6,037,323		Dasseux et al.	3/14/2000	
	4.	6,046,166		Dasseux et al.	4/4/2000	
	5.	2001/0005714 A1		Boffelli et al.	6/28/2001	
	6.	6,265,377		Dasseux et al.	7/24/2001	
	7.	6,287,590		Dasseux et al.	9/11/2001	
	8.	6,329,341		Dasseux et al.	12/11/2001	
	9.	6,376,464		Dasseux et al.	4/23/2002	
	10.	6,455,088		Dasseux et al.	9/24/2002	
	11.	6,518,412		Dasseux et al.	2/11/2003	
	12.	6,573,239		Dasseux et al.	6/3/2003	
	13.	6,602,854		Dasseux et al.	8/5/2003	
	14.	2003/0045460 A1		Fogelman et al.	3/6/2003	
	15.	6,630,450		Dasseux et al.	10/7/2003	
	16.	6,696,545		Buelow et al.	02/24/2004	
	17.	6,716,816		Dasseux et al.	4/6/2004	
	18.	6,734,169		Dasseux et al.	5/11/2004	
	19.	6,753,313		Dasseux et al.	6/22/2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	20.	IN	185761		Council of	04/28/2004		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*	Complete if Known	
	Application Number	**10/649,378**
	Filing Date	**August 26, 2003**
	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

					Scientific and Industrial Research			
	21.	WO	97/36927		Boffelli et al.	10/09/1997		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	22.	Aravinda, S., Shamala, N., Das, C. , Sriranjini, A. , Karle, I. And Balaram, P. Aromatic-Aromatic Interactions in Crystal Structures of Helical Peptide Scaffolds Containing Projecting Phenylalinine Residues, J.Am Chem Soc. 2003; 125:5308-5315.	
	23.	Ashby D, Gamble J, Vadas M, Fidge N, Siggins S, Rye K, Barter PJ. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. *Atherosclerosis*. 2001;154:113-121.	
	24.	Ashby DT, Rye K-A, Clay MA., Vadas MA, Gamble J, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. *Arteriosclerosis, Thrombosis and Vascular Biology*, 1998,18:1450-1455.	
	25.	Baker PW, Rye K-A, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical cell endothelial cells. *Journal of Lipid Research*, 1999, 40:345-353.	
	26.	Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. *J Lipid Res* 2000;41:1261-1267.	
	27.	Barter PJ, Baker PW, Rye K-A.. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. *Current Opinion in Lipidology*, 2002, 13:285-288.	
	28.	Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. *Atherosclerosis*, 1996, 121:1-12.	
	29.	Bauer ET AL. "SMS 201-995: A Very Potent and Selective Octapeptide Analogue of	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		Somatostatin with Prolonged Action" *Life Sciences* 31:1133-1140.	
	30.	Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation* 2001;104:1336-1342.	
	31.	Boffelli ET AL. "Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane" *Biochemistry* 36:10784-10792.	
	32.	Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. *Arterioscler Thromb Vasc Biol* 2000;20:2630-2635.	
	33.	Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. *Proc Natl Acad Sci* U S A. 1992;89:10316–10320.	
	34.	Brouillette ET AL. "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review" *Biochemica et Biophysica Acta* 55753:1-44.	
	35.	Burger D, Dayer J-M. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? *Autoimmunity Reviews* 2002;1:111-117.	
	36.	Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. *Biochem Biophys Res Commun.* 1997;238:61-65.	
	37.	Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G. Elevated cellular adhesion molecules in subjects with low HDL-cholesterol. *Arterioscler Thromb Vasc Biol* 2002;22:656-661.	
	38.	Canadian Pharmacists Association, Starlix General Monograph. http://cpha.infinetcomm.com/content/hcp/tools/cps_cnp_updates/starlix.cfm	
	39.	Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M, Osborn L, Chi-Rosso G, Newman B, Lobb R, Rosso M, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. *Blood* 1990;76:965-970.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	**August 26, 2003**
	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

	40.	Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species oxidation of LDL by myeloperoxidase and reactive nitrogen species. *Arterioscler Thromb Vasc Biol.* 2000;20:1716-1723.	
	41.	Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. *JAMA* 1986;256:2835-2838.	
	42.	Chiesa G, Monteggia E, Marchesi M, Lorenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. *Circ Res.* 2002;90:974-980.	
	43.	Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. *Biochem J.* 1996;314:739-742.	
	44.	Clay MA, Pyle DH, Rye K-A, Vadas MA, Gamble JR, Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. *Atherosclerosis*, 2001,157:23-29..	
	45.	Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. *rculation* 2001;103:108-112.	
	46.	Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. *Arterioscler Thromb Vasc Biol.* 1995;15:1987-1994.	
	47.	Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, Taylor G, Haskard DO. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. *Arterioscler Thromb Vasc Biol.* 1999;19:910-917.	
	48.	Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. *Journal of Clinical Investigation* 2001;107:1255-1262.	
	49.	Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E–deficient mice. *Circulation.* 2001;103:2277-2282.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	**August 26, 2003**
	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

	50.	Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. *Arterioscler Thromb Vasc Biol* 2001;21:1662-1667.	
	51.	Dansky HM, Charlton SA, Barlow CB, Tamminen M, Smith JD, Frank JS, Breslow JL. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. *J Clin Invest.* 1999;104:31-39 .	
	52.	Datta ET AL. "Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide. *J Lipid Research* 42:1096-1104.	
	53.	Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. *Am J Pathol* 2003;163:1117-1125.	
	54.	Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and Eselectin in human atherosclerosis. *J Pathol* 1993;171:223-229.	
	55.	De Caterina R, Bernini W, Carluccio MA, Liao JK, Libby P. Structural requirements for inhibition of cytokine-induced endothelial activation by unsaturated fatty acids. *J. Lipid Res.* 1998;39:1062–1070.	
	56.	Diederich ET AL. "Apolipoprotein AI and HDL_3 Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42" *Atherosclerosis* 159:313-324.	
	57.	Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, Shah PK, Nilsson J, Cercek B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuffinduced carotid injury in apoE null mice. *Biochem Biophys Res Commun.* 1999;264:465-468.	
	58.	Dooley ET AL. "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library" *Science* 2019-2022..	
	59.	Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. *Arterioscler. Thromb.* 1994;14:1775–1783.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*	Complete if Known	
	Application Number	**10/649,378**
	Filing Date	**August 26, 2003**
	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

	60.	Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. *J. Biol. Chem.* 1982;257:6653–6655.	
	61.	Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. *Proc Natl Acad Sci* U S A. 1980;77:2214-2218.	
	62.	Fogelman AM. When good cholesterol goes bad. Nat Med 2004;10:902-903.	
	63.	Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. *J. Lipid Res.* 2002;43:477–485.	
	64.	Fricker ET AL. "Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates" *The Journal of Pharmacology and Experimental Therapeutics* 274:826-832	
	65.	Fuessl ET AL. "Oral Absroption of the Somatostatin Analogue SMS 201-995: Theoretical and Practial Implications" *Clinical Science* 72: 255-257.	
	66.	Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N. Engl. J. Med.* 1999; 340: 448–454.	
	67.	Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residures of apolipoproteins AI and AII. *J Biol Chem* 1998;273:6088-6095.	
	68.	Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. *J Biol Chem* 1998;273:6080-6087.	
	69.	Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. *J Clin Invest* 2002;109:1311-1319.	
	70.	George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-lipoxygenase gene disruption attenuates atherogenesis in	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		LDL receptor–deficient mice. *Circulation*. 2001;104:1646- 1650.	
	71.	Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. *Am. J. Med.*1977;62**:** 707–714.	
	72.	Gurfinkel ET AL. "Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study" *Circulation* 105:2143-2147.	
	73.	Hamase ET AL. "Determination of Free D-Proline and D-Leucine in the Brains of Mutant Mice Lacking D-Amino Acid Oxidase Activity" *Analytical Biochemistry* 298:253-258.	
	74.	Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H, Sigal E. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor–deficient mice. *Arterioscler Thromb Vasc Biol.* 2000;20:2100-2105.	
	75.	Hardy ET AL. "An Automated High-Performance Liquid Chromatography Procedure for the Quantitation of L- and D-Amino Acids by Means of Stepwise Precolumn Derivatization" Analytical Biochemistry 291:297-299.	
	76.	Hauser ET AL. "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine" *Biochemistry* 178423-17850.	
	77.	Henricksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low density lipoproteins. *Proc Natl Acad Sci* U S A. 1981;78:6499-6503.	
	78.	Hessler JR, Robertson AL, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. *Atherosclerosis* 1979; 32:213–229.	
	79.	Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study. *Circulation* 1997;96:4219- 4225.	
	80.	Hyka ET AL. "Apolipoprotein A-I Inhibits the Production of Interleukin-1β and Tumor Necrosis Factor-α by Blocking Contact-Mediated Activation of Monocytes by	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		T Lymphocytes" *Blood* 97:2381-2389.	
	81.	Jin W, Millar JS, Broedl U, et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. *J Clin Invest* 2003;111:357-362.	
	82.	Jones ET AL. "Computer Programs to Identify and Classify Amphipathic α Helical Domains" *Journal of Lipid Research* 33:287-296.	
	83.	Karle, I., Gopi, H., and Balaram, P. Crystal structure of hydrophobic 19-residue peptide helix containing three centrally located D amino acids PNAS 2003;100:24:13946-13951	
	84.	Karle, I, Prasad, S. and Balaram, P. A combined extented and helical backbone for Boc-(Ala-Leu-Ac7C)2-OME, Peptides Res. 2004; 63:174-180	
	85.	Ko Y, Haring R, Stiebler H, Wieczorek AJ, Vetter H, Sachinidis A. Highdensity lipoprotein reduces epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. *Atherosclerosis* 1993;99: 253–259.	
	86.	Kullman ET AL.) "Evaluation of the Enantiomeric Composition of Amino Acids in Tobacco" *Chirality* 11:669-673.	
	87.	Kume N, Cybulsky MI, Gimbrone Jr MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. *Journal of Clinical Investigation* 1992;90:1138-1144.	
	88.	Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. *Cell* 1991;65:859-873.	
	89.	Lee SH, Oe T, Blair IA. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. *Science* 2001;292:2083-2086.	
	90.	Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. *Proc. Natl. Acad. Sci.* USA 1993:90 : 12040–12044.	
	91.	Li H, Cybulsky MI, Gimbrone MA, Jr., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. *Arteriosclerosis and Thrombosis* 1993;13:197-204.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*	Complete if Known	
	Application Number	**10/649,378**
	Filing Date	**August 26, 2003**
	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

	92.	Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation* 2002;105:1135-1143.	
	93.	Lundin ET AL. "Absorption of Intragastrically Administered DDAVP in Conscious Dogs" *Life Sciences* 38:703-709.	
	94.	Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. *Circ Res.* 2002;91:120- 126.	
	95.	Merrifield ET AL. "Retro and Retroenantio Analogs of Cecropin-Melittin Hybrids" *Proc Natl Acad Sci USA* 92: 3449-3453.	
	96.	Murugesan G, Sa G, Fox PL. High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor. *Circ. Res.* 1994;74 : 1149–1156.	
	97.	Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of apoA-I/phosphosphatidycholine discs on plasma lipoproteins in humans.. *Arterioscler Thromb Vasc Biol.* 1999;19:979-989.	
	98.	Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-b-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. *J Lipid Res* 2001;42:1586-1593.	
	99.	Navab ET AL. "Oral Administration of an Apo A-I Mimetic Peptide Synthesized from D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol" *Circulation* 105: 290-292.	
	100.	Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. *J. Lipid Res.* 2004; 45: 993–1007.	
	101.	Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-□ high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apoE-null mice. *Circulation* 2004;109:r120-r125.	
	102.	Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. *Arterioscler*	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		Thromb Vasc Biol 2001;21:481-488.	
	103.	Navab M, Hama S, Hough G et al. Oral synthetic phospholipids (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. *Circulation* 2003;108:1735-1739.	
	104.	Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. *J Lipid Res* 2001;42:1308-1317.	
	105.	Navab M, Hama-Levy, S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. *J. Clin. Invest.* 1997; 99: 2005–2019.	
	106.	Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H,, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. *Journal of Clinical Investigation* 1991;88:2039-2046.	
	107.	Nievelstein PF, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima two hours after bolus infusion of low density lipoprotein: A deep-etch and immuno-localization study of ultra-rapidly frozen tissue. *Arteriosclerosis and Thrombosis* 1991;11:1795-1805.	
	108.	Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson SR, Harker LA. Anti- VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in nonhuman primates. *J Vasc Surg* 1997;26:87-93.	
	109.	Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. *Nature* 1998;394:200- 203.	
	110.	O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. *Circulation* 1996;93:672-82.	
	111.	O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. *Circulation* 2001;104:1978–1983.	
	112.	Oguchi S, Dimayuga P, Zhu J, Chyu KY, Yano J, Shah PK, Nilsson J, Cercek B. Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. *Arterioscler Thromb Vasc Biol* 2000;20:1729-1736.	
	113.	Owens ET AL. "Apolipoprotein A-I and its Amphipathic Helix Peptide Analogues Inhibit Human Immunodeficiency Virus-Induced Syncytium Formation" *J Clin Invest* 86: 1142-1150.	
	114.	Panizzutti ET AL. "A New Strategy to Decrease N-methyl-D-aspartate (NMDA) Receptor Coactivation: Inhibition of D-serine Synthesis by Converting Serine Racemase into an Eliminase" *PNAS* 98:5294-5299.	
	115.	Papo N, Oren Z, Pag U, et al. The consequence of sequence alteration of an amphipathic □-helical antimicrobial peptide and its diastereomers. *J. Biol. Chem.* 2002;277(37): 33913-33921.	
	116.	Pappenheimer ET AL. "Intestinal Absorption and Excretion of Octapeptides Composed of D Amino Acids" *Proc Natl Acad Sci USA* 91: 1942-1945.	
	117.	Parthasarathy S, Santanam N. Mechanisms of oxidation antioxidants, and atherosclerosis. *Curr Opin Lipidol* 1994;5:371-375.	
	118.	Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of Creactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation.* 2001;103:2531-2534.	
	119.	Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation.* 2000;102:2165-2168.	
	120.	Peng ET AL. "Effects of L-glutamate, D-aspartate, and Monensin on Glycolytic and Oxidative Glucose Metabolism in Mouse Astrocyte Cultures: Further Evidence that Glutamate Uptake is Metabolically Driven by Oxidative Metabolism" *Neurochemistry International* 38:437-443.	
	121.	Ou J, Geiger T, Zhijun O, et al. AP-4F, antennapedia peptide linked to an amphipathic □ helical peptide, increases the efficiency of lipofectamine-mediated gene transfection in endothelial cells. *Biochem Biophys Res Commun* 2003;305:605-610.	
	122.	Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemic and sickle cell disease. *Circulation* 2003;107:2337-2341.	
	123.	Ou Z, Ou J, Ackerman AW et al. L-4F, an apolipoprotein A-I mimetic, restores nitric	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. *Circulation* 2003;107:1520-1524.	
	124.	Ranganathan, D, Kurur, S, Kunwar, A, Sarma, A, Vairamani, M, Karle, I. Channel-forming, self-assembling, bishelical amphiphilic peptides: design, synthesis and crystal structure of Py(Aibn)21 n=2, 3, 4. J. Peptide Res. 2000 56:416-426	
	125.	Reape TJ, Groot PH. Chemokines and atherosclerosis. *Atherosclerosis* 1999;147:213-225.	
	126.	Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDLassociated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. *Arterioscler Thromb Vasc Biol* 2001;21:542- 547.	
	127.	Reddy ST, Nguyen JT, Grijalva V, et al. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. *Arterioscler Thromb Vasc Biol* 2004;24:1676-1681.	
	128.	Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. *Circulation* 2002;105:2-4.	
	129.	Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. *Circulation* 2001;104:2447-2452.	
	130.	Sattler W, Stocker R. Greater selective uptake by Hep G2 cells of highdensity lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. *Biochem J.* 1993;294:771-778.	
	131.	Segrest ET AL. "The Amphipathic Helix in the Exchangeable Apolipoproteins: A Review of Secondary Structure and Function" *J Lipid Research* 33:141-166.	
	132.	Shah PK, Nilsson J, Kaul S. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. *Circulation*, 1998:97(8): 780-785.	
	133.	Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B. High-dose recombinant apolipoproteins A-IMilano mobilizes tissue cholesterol and rapidly	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		reduces plaque lipid and macrophage content in apolipoprotein Edeficient mice: potential implications for acute plaque stabilization. *Circulation.* 2001;103:3047–3050.	
	134.	Shih D.M., Xia Y-R., Wang X-P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. *J. Biol. Chem.*, 2000;275:17527-17535.	
	135.	Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta integrin. *J Clin Invest* 1999;103:613-625.	
	136.	Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. *JAMA* 2003:289:1675-1680.	
	137.	Sing ET AL. "Innate Defences Against Viraemia" *Rev Med Virol* 10:395-403.	
	138.	Singh IP, Baron S. Innate defences against viremia. *Rev Med Virol* 2000;10:395-403.	
	139.	Sorescu D, Szocs K, Griendling KK. NAD(P)H oxidases and their relevance to atherosclerosis. *Trends Cardiovas Med* 2001;11:124-131.	
	140.	Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. *Circulation.* 2002;105:1399- 1402.	
	141.	Springer TA. Adhesion receptors of the immune system. *Nature* 1990;346:425-434.	
	142.	Srinivas ET AL. "Antivrial Effects of Apolipoprotein A-I and Its Synthetic Amphipathic Peptide Analogs" *Virology* 176:48-57.	
	143.	Stannard AK, Khan S, Graham A, Owen JS, Allen SP. Inability of plasma high-density lipoproteins to inhibit cell adhesion molecule expression in human coronary artery endothelial cells. *Atherosclerosis* 2001;154:31-38.	
	144.	Starlix MC—Amino Acid Fact Sheet. http://www.starlix.com/media_center/content/pages/amino.htm.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

	145.	Sugatani J, Miwa M, Komiyama Y, Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. *J. Lipid Mediators Cell Signal.* 1996:13:73–88.	
	146.	Tsao ET AL.) "Hibernation-induction Peptide and Cell Death: [D-Ala^2, D-Leu^5]enkephalin Blocks Bax-related Apoptotic Processes" *European Journal of Pharmacology* 428:149-151.	
	147.	Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. *Circulation* 2002;106:484-490.	
	148.	Van Lenten ET AL. "Acute Influenza A Infection Promotes Increased Macrophage Infiltration into the Artery Wall that is Prevented by Apolipoprotein A-I" *Circulation* 104(suppl II):II-470. Abstract.	
	149.	Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. *J Clin Invest* 1995;96:2758- 2767.	
	150.	Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001;103:2283-2288.	
	151.	Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. *Circulation* 2002; 106:1127-1132.	
	152.	Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. *Circulation.* 2002;106:1439-1441.	
	153.	Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. *Arterioscler Thromb Vasc Biol* 1995;15:2-10.	
	154.	Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized-low density	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	**10/649,378**
INFORMATION DISCLOSURE	Filing Date	**August 26, 2003**
STATEMENT BY APPLICANT	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
(use as many sheets as necessary)	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		lipoprotein. *J Clin Invest* 1995;95:774-782.	
	155.	Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. *J Clin Invest* 1995;96:2882-2891.	
	156.	Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. *J Biol Chem.* 1999;274:33143-33147.	
	157.	Yamashita S, Maruyama T, Hirano K, et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. *Atherosclerosis* 2000;152:271-285.	
	158.	Yan D, Navab M, Bruce C et al. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. *J Lipid Res* 2004;45:1852-1858.	
	159.	Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. *J. Clin. Invest.* 1988;82: 803–807.	
	160.	Zeiher AM, Schachinger V. Hohnloser SH, et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. *Circulation* 1994;89:2525-2532.	
	161.	Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. *J Biol Chem* 2002;277:46116-46122.	
	162.	Zhang WJ, Stocker R, McCall MR, Forte TM, Frei B. Lack of inhibitory effect of HDL on TNFalpha-induced adhesion molecule expression in human aortic endothelial cells. *Atherosclerosis* 2002;165:241-249.	
	163.	Zhao L, Cuff CA, Moss e, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase deficient macrophages associated with reduced atherosclerosis in a ouse model of familial hypercholesterolemia. *J Biol Chem* 2002;277:35350-35356.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	**10/649,378**
Filing Date	**August 26, 2003**
First Named Inventor	**Alan M. Fogelman**
Group Art Unit	**1654**
Examiner Name	**Jeffrey E. Russel**
Attorney Docket Number	**407T-911310US**
Date Submitted	**May 18, 2005**

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	1.	4,684,520		Bertelli		
	2.	5,298,490		Heavner et al		
	3.	5,595,973		Bogden		
	4.	2002/0042441		Acton et al		
	5.	2003/0125260		Haviv et al		
	6.	2003/0027769		Scialdone et al		
	7.	2003/0040505		Fogelman et al		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	8.	WO	96/41815 A2		Dussourd et al.	12/27/1996		
	9.	WO	99/16408		Dasseux et al.	04/08/1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	10.	Gorski,A et al. Cyclolinopeptide: a novel immunosuppressive agent with potential anti-lipemic activity. Arch. Immunol. Ther Exp. 1999; 47(3): 143-153.	
	11.	Kluczyk, A. Siemion, TH:ca, Szewczuk, Z., and Wieczorek, Z. The immunosuppressive activity of peptide fragments of viccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion. Peptides 2002; 23: 823-834	
	12.	Mathison, R., Lo, P., Moore, G., Scott, B. and Davison, J. Attenuation of Intestinal and Cardiovascular Anaphylaxis by the Salivary Gland Tripeptide FEG and Its D-isometric Analog feG. Peptides 1998; 19 (6) 1037-1042	
	13.	Mathison, R., Woodman, R. and Davison, J. Regulation of leukocyte adhesion to heart by the tripeptides feG and feG(NH2) Can. J. Physiol. Pharm. 2001; 79: 785-792.	
	14.	Mathison, R., Befus, A., Davison, J. and Woodman, R. Modulation of neutrophil	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*	Complete if Known	
	Application Number	**10/649,378**
	Filing Date	**August 26, 2003**
	First Named Inventor	**Alan M. Fogelman**
	Group Art Unit	**1654**
	Examiner Name	**Jeffrey E. Russel**
	Attorney Docket Number	**407T-911310US**
	Date Submitted	**May 18, 2005**

		function by the tripeptide feG. BMC Immunology 2003; 4: 1471-2172.	
	15.	Mathison, R., Lo, P., Tan, R. and Davison, J. The tripeptide feG reduces endotoxin-provoked perturbation of intestinal motility and inflammation. Neurogastrointerol 2001; 13: 599-603.	
	16.	Mathison, R. Davison, J. and Metwally, E. Identification of a binding site for the anti-inflammatory tripeptide feG. Peptides 2003; 24: 1221-1230.	
	17.	Metwally, E., Befus, A., Davison, J. and Mathison, R. Probing for submandibular gland peptide-t receptors on leukocytes with biotinylated-Lys [Gly]6-AGP-T. Biochimica et Biophysica Acta 1593 2002; 37-44	
	18.	Metwally, E., Davison, J. and Mathison, R. Tyrosine is detrimental to the biological activity of submandibular gland peptide-T (SGP-T) Proc. West Pharmacol. Soc. 1999; 42: 65-66	
	19.	Metwally, E., Pires, J., Moore, G., Befus, D., Davison, J. and Mathison, R. Submandibular gland tripeptide FEG (Phe-Glu-Gly) and analogues: keys to structure determination. Peptides 2002; 23: 193-199.	
	20.	Metwally, E., Ismail, A., Davison, J. and Mathison, R. A tree based algorithm for determining the effects of solvation on the structure of salivary gland tripeptide NH3+-D-PHE-D-GLU-GLY-COO. Biophysical Journal 2003; 65: 1503-1511.	
	21.	Siemion, I. And Wieczorek, Z. Antiadhesive peptides as the inhibitors of mycobacterium kansasii phagocytosis. Peptides 2003; 24: 623-628.	
	22.	Seimion, I. Et al. Analogs of RGDVY and GRGD peptides inhibit mycobacterium kansaii phagocysis. Peptides 2003; 24: 1109-1115.	
	23.	Sundal, E. Thymopentin prophylactic treatment in patients with recurrent respirator infections. Br. J Clin Pract. 1993;47: 198-204	
	24.	Szewczuk, Z. Immunosuppressory activity of the cyclodimetric peptide with RGD-sequences. Acta. Biochimica Polonica 2001; 48: 121-130.	
	25.	Tan et al. The carboxamine feG(NH2) inhibits endotoxin perturbation of intestinal motility. Eurp. Jol. Of Pharm. 2000; 203-205.	
	26.	Turesin, F. et al. The tripeptide feG ameliorates systemic inflammatory responses to rat intestinal anaphylaxis. BMC Physiology 2002; 2(13) 1472-6793.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.